Publications by authors named "Curtis Dunshee"

Claim this Profile
C
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078].
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, Fred Saad, Ugo De Giorgi, Curtis Dunshee

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, Joan Carles, André P Fay, Curtis Dunshee

Lancet· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.
Neeraj Agarwal, Arun A Azad, Joan Carles, André P Fay, Nobuaki Matsubara, Curtis Dunshee

Lancet· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial.
Jose De La Cerda, Laurence Belkoff, Kevin D Courtney, Elan Diamond, James D'Olimpio, Curtis Dunshee

Target Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.
Nobuaki Matsubara, Arun A Azad, Neeraj Agarwal, Fred Saad, Ugo De Giorgi, Curtis Dunshee

Lancet Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.
Andre P Fay, Karim Fizazi, Nobuaki Matsubara, Arun A Azad, Fred Saad, Curtis Dunshee

Lancet Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 study.
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, Joan Carles, Andre P Fay, Curtis Dunshee

Future Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, Fred Saad, Ugo De Giorgi, Curtis Dunshee

Eur J Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer.
Neeraj Agarwal, Arun A Azad, Joan Carles, Andre P Fay, Nobuaki Matsubara, Curtis Dunshee

Future Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, Joan Carles, Andre P Fay, Curtis Dunshee

Nat Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States.
Rana R McKay, Alicia K Morgans, Neal D Shore, Curtis Dunshee, Geeta Devgan

Cancer Treat Rev· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, Joan Carles, Andre P Fay, Curtis Dunshee

Nat Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Neeraj Agarwal, Arun A Azad, Joan Carles, Andre P Fay, Nobuaki Matsubara, Curtis Dunshee

Lancet· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer.
Jose De La Cerda, Curtis Dunshee, Lawrence Gervasi, Paul Sieber, Laurence Belkoff

Target Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
David F Penson, Andrew J Armstrong, Raoul S Concepcion, Neeraj Agarwal, Carl A Olsson, Curtis J Dunshee

Prostate Cancer Prostatic Dis· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer.
Neeraj Agarwal, Arun Azad, Neal D Shore, Joan Carles, Andre P Fay, Curtis Dunshee

Future Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
David F Penson, Andrew J Armstrong, Raoul S Concepcion, Neeraj Agarwal, Carl A Olsson, Curtis J Dunshee

Prostate Cancer Prostatic Dis· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design.
Neeraj Agarwal, Arun Azad, Neal D Shore, Joan Carles, Andre P Fay, Curtis Dunshee

Future Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.
Arnulf Stenzl, Curtis Dunshee, Ugo De Giorgi, Boris Alekseev, Taro Iguchi

Eur Urol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
Neal D Shore, Charles G Drake, Daniel W Lin, Charles J Ryan, Kelly L Stratton, Curtis Dunshee

Prostate· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to M.A.N. Şendur et al and J. Michels.
David F Penson, Andrew J Armstrong, Raoul Concepcion, Neeraj Agarwal, Carl Olsson, Curtis Dunshee

J Clin Oncol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
David F Penson, Andrew J Armstrong, Raoul Concepcion, Neeraj Agarwal, Carl Olsson, Curtis Dunshee

J Clin Oncol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis